Healthcare Services

Spinal Muscular Atrophy Market Forecast Assessing Growth Potential And Industry Direction

June 3, 2026June 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Value Outlook For The Spinal Muscular Atrophy Market Through 2030?

The spinal muscular atrophy market has seen a rapid increase in size over recent years. Projected figures indicate it will grow from $4 billion in 2025 to $4.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.2%. This growth observed in the past can be attributed to several factors, including the approval of breakthrough SMA therapies, an increase in genetic testing, elevated awareness from advocacy groups, significant investments in clinical trials, and funding allocated for rare diseases.

The market size for spinal muscular atrophy is projected to experience substantial growth in the upcoming years, with an expectation to reach $7.34 billion by 2030 at a compound annual growth rate (CAGR) of 12.9%. The expansion during the forecast period is primarily driven by the introduction of next-generation gene therapies, increased global screening adoption, wider treatment access, improved patient survival outcomes, and ongoing pipeline drug development. Significant trends identified for this period include early genetic diagnosis, the broadening availability of disease-modifying therapies, widespread newborn screening programs, personalized treatment protocols, and effective long-term disease management strategies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp

Which Significant Factors Are Encouraging Growth In The Spinal Muscular Atrophy Market?

The increasing occurrence of rare genetic diseases is expected to propel the growth of the spinal muscular atrophy market going forward. These disorders arise from gene mutations, affecting a small segment of the population and often resulting in severe, chronic health problems. The growing prevalence of rare genetic diseases can be attributed to improvements in diagnostic technologies, heightened awareness, and better access to genetic testing, leading to more identified and reported cases. Spinal muscular atrophy (SMA) is a rare genetic disorder that exemplifies both the challenges and opportunities in understanding inherited diseases, highlighting the importance of advancing research into genetic conditions. For instance, in July 2023, a report published by the Office for National Statistics, a UK-based government department, indicated that genetic testing of SMN1 has enabled precise epidemiological studies, revealing that SMA occurs in 1 of 10,000 to 20,000 live births and that more than 95% of affected patients are homozygous for SMN1 deletion. Therefore, the rising prevalence of rare genetic diseases will drive the growth of the spinal muscular atrophy market.

Which Segment Divisions Form The Structure Of The Spinal Muscular Atrophy Market?

The spinal muscular atrophy market covered in this report is segmented –

1) By Type: Type 1 (Severe), Type 2 (Intermediate), Type 3 (Mild), Type 4 (Adult)

2) By Age: Pediatric, Adults

3) By Treatment: Drug Therapy, Gene Therapy

4) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegments:

1) By Type 1 (Severe): Infantile-Onset SMA, Severe Progressive SMA

2) By Type 2 (Intermediate): Early-Onset SMA, Non-progressive SMA

3) By Type 3 (Mild): Juvenile-Onset SMA, Mild Progressive SMA

4) By Type 4 (Adult): Adult-Onset SMA, Late-Onset SMA

Which Trends Are Shaping The Spinal Muscular Atrophy Market Landscape?

Leading companies in the spinal imaging market are concentrating on creating technological improvements to elevate imaging efficiency, connectivity, and the delivery of care within radiology networks. These innovations are intended to foster greater collaboration among radiology professionals, streamline workflows, and address the rising demand for high-performance diagnostic imaging. For example, in October 2024, Koninklijke Philips N.V., a healthcare technology and imaging solutions provider based in the Netherlands, unveiled the Philips Radiology Operations Command Center (ROCC), an advanced vendor-agnostic platform engineered to bolster real-time communication across radiology teams. This solution facilitates remote collaboration among technologists, radiologists, and imaging operations across multiple sites through secure telepresence capabilities. By dismantling conventional communication obstacles and centralizing oversight, ROCC considerably enhances operational efficiency and optimizes imaging care delivery across diverse radiology settings.

Who Are The Key Market Participants In The Spinal Muscular Atrophy Market?

Major companies operating in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., Beijing Jinlan Gene Technology Co. Ltd, Sarepta Therapeutics, Amicus Therapeutics, Audentes Therapeutics, Solid Biosciences

Access The Complete Spinal Muscular Atrophy Market Report:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

Which Region Is The Primary Market For The Spinal Muscular Atrophy Market?

North America was the largest region in the spinal muscular atrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Spinal Muscular Atrophy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=20965&type=smp

Browse Through More Reports Similar to the Global Spinal Muscular Atrophy Market 2026, By The Business Research Company

Spine Biologics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/spine-biologics-global-market-report

Muscle Wasting Disorders Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/muscle-wasting-disorders-global-market-report

Duchenne Muscular Dystrophy Dmd Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-dmd-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795